ArticleBMC cancer2019
Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Harmonization Framework for Translating Clinical Cancer Staging Systems for Public Health and Surveillance Use in Low- and Middle-Income Countries: Validation Using Indian Cancer Registry Data.Cancer medicine · 2026Article
- Estimating the number of people living with metastatic breast cancer: a population-based retrospective cohort study using linked health data.The Lancet regional health. Western Pacific · 2026Article
- Clinical and treatment profile with five-year survival analysis of colorectal cancer from Himalayan state of India.Ecancermedicalscience · 2025Article
- Collecting routine and timely cancer stage at diagnosis by implementing a cancer staging tiered framework: the Western Australian Cancer Registry experience.BMC health services research · 2024Article
- Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancer.BMC cancer · 2023Article
- Defining aggressive prostate cancer: a geospatial perspective.BMC cancer · 2023Article
- "Currently flying blind" Stakeholders' perceptions of implementing statewide population-based cancer staging at diagnosis into the Western Australian Cancer Registry: a rapid qualitative process evaluation of the WA Cancer Staging Project.BMC health services research · 2023Article
- Analysis of the surgical approach in prostate cancer staging: results from the surveillance, epidemiology and end results program.Scientific reports · 2023Article
- Determining cancer stage at diagnosis in population-based cancer registries: A rapid scoping review.Frontiers in health services · 2023Article
- Socioeconomic disparities in colorectal cancer survival: contributions of prognostic factors in a large Australian cohort.Journal of cancer research and clinical oncology · 2022Article
- Prediction of lymph node metastasis in oral tongue squamous cell carcinoma using the neutrophil-to-lymphocyte ratio and platelet-to-neutrophil ratio.Journal of clinical laboratory analysis · 2021Article
- Crude probability of death for cancer patients by spread of disease in New South Wales, Australia 1985 to 2014.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn 2017, the New South Wales Cancer Registry (NSWCR) participated in a project, supported by Cancer Australia, aiming to provide national stage data for melanoma, prostate, colorectal, breast, and lung cancers diagnosed in 2011. Simplified business rules based on the American Joint Committee for Cancer (AJCC) Tumour-Node-Metastasis (TNM) stage were applied to obtain Registry-Derived (RD) stage, defined as the best estimate of TNM stage at diagnosis using routine notifications available within cancer registries. RD-stage was compared with Degree of Spread (DoS), which has been recorded for all applicable cancers in NSWCR at a population-based level since 1972, and a summary AJCC-TNM stage group, which has been collected variably since 2006. For each of the five high incidence cancers, we compared the level of improvements RD-staging provided in terms of completeness and accuracy (alignment to more clinically relevant AJCC-TNM) over DoS.
methodsFor each of the five cancers, stage data were extracted from NSWCR pre- and post- RD-staging to compare data completeness across all three staging systems. The alignment between DoS/RD-stage and AJCC-TNM was compared, as were the expected and observed cross-tabulated frequency distributions using a subset of NSWCR data. To determine differences between use of DoS, RD-stage, and AJCC-TNM in an epidemiological analysis, we compared survival models developed from each of the three stage variables.
resultsWe found RD-staging provided greatest stage data completeness and alignment to AJCC-TNM for prostate cancers, followed by breast, then melanoma and lung cancers. For colorectal cancer, summary stage from DoS was confirmed as an equivalent surrogate staging system to both AJCC-TNM and RD-stage.
conclusionsThis analysis provides an evidence-based approach that can be used to inform decision-making for resource planning and potential implementation of a new stage data field in population-based cancer registries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.